Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

10.1080/15384047.2016.1139268<br/>Jessica D. Sun

from Cancer via ola Kala on Inoreader http://ift.tt/1oUsvzv
via IFTTT